Search hospitals > Delaware > Newark
Medical Oncology Hematology Consultants PA
Claim this profileNewark, Delaware 19713
Global Leader in Breast Cancer
Global Leader in Lung Cancer
Conducts research for Cancer
Conducts research for Breast cancer
Conducts research for Non-Small Cell Lung Cancer
250 reported clinical trials
3 medical researchers
Summary
Medical Oncology Hematology Consultants PA is a medical facility located in Newark, Delaware. This center is recognized for care of Breast Cancer, Lung Cancer, Cancer, Breast cancer, Non-Small Cell Lung Cancer and other specialties. Medical Oncology Hematology Consultants PA is involved with conducting 250 clinical trials across 383 conditions. There are 3 research doctors associated with this hospital, such as Gregory A. Masters, Jamal Misleh, MD, and Mark E. Borowsky.Area of expertise
1Breast Cancer
Global LeaderHER2 negative
ER positive
Stage IV
2Lung Cancer
Global LeaderStage IV
Stage II
Stage I
Top PIs
Gregory A. MastersHelen F Graham Cancer Center6 years of reported clinical research
Expert in Breast Cancer
Expert in Breast cancer
133 reported clinical trials
213 drugs studied
Jamal Misleh, MDMedical Oncology Hematology Consultants, PA3 years of reported clinical research
Expert in Breast Cancer
Studies Pancreatic Cancer
28 reported clinical trials
48 drugs studied
Mark E. BorowskyJersey Shore Medical Center6 years of reported clinical research
Studies Fallopian Tube Cancer
Studies Ovarian Cancer
3 reported clinical trials
11 drugs studied
Clinical Trials running at Medical Oncology Hematology Consultants PA
Lung Cancer
Breast Cancer
Cancer
Prostate Cancer
Skin Cancer
Breast cancer
Colorectal Cancer
Esophageal cancer
Bladder Cancer
Ovarian Cancer
Durvalumab
for Lung Cancer
This phase III trial compares durvalumab to the usual approach (patient observation) after surgery for the treatment of patients with early-stage non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The usual approach for patients who are not in a study is to closely watch a patient's condition after surgery and to have regular visits with their doctor to watch for signs of the cancer coming back. Usually, patients do not receive further treatment unless the cancer returns. This study will help determine whether this different approach with durvalumab is better, the same, or worse than the usual approach of observation. Giving durvalumab may help patients live longer and prevent early-stage non-small cell lung cancer from coming back as compared to the usual approach.
Recruiting2 awards Phase 38 criteria
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Treatment Timing
for Non-Small Cell Lung Cancer
This phase III trial compares standard therapy given after surgery (adjuvant) to standard therapy given before and after surgery (perioperative) in treating patients with stage II-IIIB non-small cell lung cancer (NSCLC) that can be removed by surgery (resectable). The usual approach for patients with resectable NSCLC is chemotherapy and/or immunotherapy before surgery, after surgery, or both before and after surgery. This study is being done to find out which approach is better at treating patients with lung cancer. Treatment will be administered according to the current standard of care at the time of enrollment. Chemotherapy options may include cisplatin, carboplatin, pemetrexed, gemcitabine, docetaxel, and vinorelbine at standard doses according to the treating physician. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Pemetrexed is in a class of medications called antifolate antineoplastic agents. It works by stopping cells from using folic acid to make deoxyribonucleic acid (DNA) and may kill tumor cells. Gemcitabine is a chemotherapy drug that blocks the cells from making DNA and may kill tumor cells. Docetaxel is in a class of medications called taxanes. It stops tumor cells from growing and dividing and may kill them. Other chemotherapy drugs, such as vinorelbine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading . Immunotherapy with monoclonal antibodies, such as nivolumab, pembrolizumab, and atezolizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Starting treatment with chemotherapy and immunotherapy prior to surgery and continuing treatment after surgery may be a more effective treatment option than adjuvant therapy alone in patients with stage II-IIIB resectable NSCLC.
Recruiting2 awards Phase 34 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Medical Oncology Hematology Consultants PA?
Medical Oncology Hematology Consultants PA is a medical facility located in Newark, Delaware. This center is recognized for care of Breast Cancer, Lung Cancer, Cancer, Breast cancer, Non-Small Cell Lung Cancer and other specialties. Medical Oncology Hematology Consultants PA is involved with conducting 250 clinical trials across 383 conditions. There are 3 research doctors associated with this hospital, such as Gregory A. Masters, Jamal Misleh, MD, and Mark E. Borowsky.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.